In the top M&A, Becton Dickinson agreed to acquire Edwards Lifesciences' critical care product group for $4.2bn in cash. Edwards first announced plans to spin off the unit in December 2023 to focus on its structural heart business and associated portfolio of repair and replacement valves for cardiovascular disease patients. Edwards’ critical care group includes advanced hemodynamic patient monitoring tools, predictive software, and sensors used to help inform clinician decision making. The acquisition aims to expand BD's portfolio of smart-connected products, with complementary monitoring technology, AI-enabled clinical decision tools, as well as an innovation pipeline. Financing reached $6.9bn in biopharma, $631m in device, and $196m in diagnostics.
Deals in Depth: June 2024
Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.
More from Deal-Making
Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.
An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.
After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.
More from In Vivo
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.